Literature DB >> 19362742

CTLA4Ig gene transfer alleviates abortion in mice by expanding CD4+CD25+ regulatory T cells and inducing indoleamine 2,3-dioxygenase.

Weihong Li1, Bin Li, Wei Fan, Lihong Geng, Xiaohong Li, Lei Li, Zhongying Huang, Shangwei Li.   

Abstract

Successful pregnancy requires a state of immunological tolerance since normally the maternal immune system does not reject the semi-allogeneic conceptus. Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), a ligand for B7, delivers negative signals to antigen presenting cells (APCs) to compete with CD28 for binding to B7 molecules and down-regulate proinflammatory responses, thus inhibiting T cell activation. Using CBA/J x DBA/2 matings as an abortion-prone model, we observed that adenovirus-mediated CTLA4Ig (Ad-CTLA4Ig) gene transfer improves pregnancy outcome. Ad-CTLA4Ig therapy skewed the ability of serum cytokine production toward a Th2 bias. Flow cytometry revealed that Ad-CTLA4Ig administration expanded peripheral CD4(+)CD25(+) regulatory T cell populations in CBA/J x DBA/2 matings. Furthermore, Ad-CTLA4Ig administration induced indoleamine 2,3-dioxygenase (IDO) and Foxp3 mRNA expression at the materno-fetal interface. Our results demonstrate that adenovirus-mediated CTLA4Ig gene transfer improves pregnancy outcome in a murine model of abortion by expanding the CD4(+)CD25(+) regulatory T cell population and inducing IDO mRNA expression.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19362742     DOI: 10.1016/j.jri.2008.11.006

Source DB:  PubMed          Journal:  J Reprod Immunol        ISSN: 0165-0378            Impact factor:   4.054


  9 in total

Review 1.  Immunomodulatory effects of sex hormones: requirements for pregnancy and relevance in melanoma.

Authors:  Elizabeth Ann L Enninga; Shernan G Holtan; Douglas J Creedon; Roxana S Dronca; Wendy K Nevala; Simona Ognjanovic; Svetomir N Markovic
Journal:  Mayo Clin Proc       Date:  2014-04       Impact factor: 7.616

2.  Association between cytokine profile and transcription factors produced by T-cell subsets in early- and late-onset pre-eclampsia.

Authors:  Vanessa R Ribeiro; Mariana Romao-Veiga; Graziela G Romagnoli; Mariana L Matias; Priscila R Nunes; Vera Therezinha M Borges; Jose C Peracoli; Maria Terezinha S Peracoli
Journal:  Immunology       Date:  2017-06-19       Impact factor: 7.397

3.  CTLA-4-Ig therapy diminishes the frequency but enhances the function of Treg cells in patients with rheumatoid arthritis.

Authors:  Crisol Álvarez-Quiroga; Carlos Abud-Mendoza; Lesly Doníz-Padilla; Amida Juárez-Reyes; Adriana Monsiváis-Urenda; Lourdes Baranda; Roberto González-Amaro
Journal:  J Clin Immunol       Date:  2011-04-13       Impact factor: 8.317

Review 4.  The T helper type 17/regulatory T cell paradigm in pregnancy.

Authors:  Ana Sofia Figueiredo; Anne Schumacher
Journal:  Immunology       Date:  2016-05       Impact factor: 7.397

Review 5.  Indoleamine 2,3-dioxygenase and dendritic cell tolerogenicity.

Authors:  Jamie L Harden; Nejat K Egilmez
Journal:  Immunol Invest       Date:  2012       Impact factor: 3.657

Review 6.  To drive or be driven: the path of a mouse model of recurrent pregnancy loss.

Authors:  Elizabeth A Bonney; Stephen A Brown
Journal:  Reproduction       Date:  2014-04-08       Impact factor: 3.906

Review 7.  Regulation of the innate immune cells during pregnancy: An immune checkpoint perspective.

Authors:  Wen-Xuan Li; Xiang-Hong Xu; Li-Ping Jin
Journal:  J Cell Mol Med       Date:  2021-10-28       Impact factor: 5.310

8.  Evaluating the Effects of BPA and TBBPA Exposure on Pregnancy Loss and Maternal-Fetal Immune Cells in Mice.

Authors:  Jasmine M Reed; Philip Spinelli; Sierra Falcone; Miao He; Calla M Goeke; Martha Susiarjo
Journal:  Environ Health Perspect       Date:  2022-03-28       Impact factor: 9.031

Review 9.  Immune Checkpoint Molecules in Reproductive Immunology.

Authors:  Eva Miko; Matyas Meggyes; Katalin Doba; Aliz Barakonyi; Laszlo Szereday
Journal:  Front Immunol       Date:  2019-04-18       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.